Skip to main content

Table 1 Clinical and molecular features of cancer cohorts

From: Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups

  BRAFmutant BRAFwild type P value
N 214 122 -
Average Age (years) 74.1 67.1 <0.0001
Gender - female 139/214 (65.0%) 49/122 (40.2%) <0.0001
Tumour Location (Proximal) 164/192 (85.4%) 28/117 (23.9%) <0.0001
AJCC stage I/II 110/170 (64.7%) 58/111 (52.3%) <0.05
AJCC stage III/IV 60/170 (35.3%) 53/111 (47.7%)
Mucinous 37/96 (38.5%) 3/42 (7.1%) <0.0001
Differentiation (poor) 38/96 (39.6%) 12/42 (28.6%) 0.2
MSI High 120/214 (56.1%) 0 -
CIMP High 154/205 (75.1%) 3/121 (2.5%) <0.0001
p53 Mutation 29/107 (27.1%) 40/80 (50.0%) 0.002
KRAS Mutation 0 38/80 (47.5%) -
PRDM5 Methylation 77/214 (36.0%) 4/122 (3.3%) <0.0001
PRDM5 PMR 27 3 <0.0001
Nuclear Beta-Catenin 36/92 (39.1%) 36/42 (85.7%) <0.0001
  1. Significant p values indicated in bold text.